Aromatic L-amino acid decarboxylase inhibitor

From Wikipedia, the free encyclopedia
  (Redirected from DOPA decarboxylase inhibitor)
Jump to: navigation, search
"DDCI" redirects here. For the software company, see DDC-I. For the Deputy Director of the CIA, see Deputy Director of the Central Intelligence Agency.

An aromatic L-amino acid decarboxylase inhibitor (synonyms: DOPA decarboxylase inhibitor, DDCI and AAADI) is a drug which inhibits the synthesis of dopamine by the enzyme aromatic L-amino acid decarboxylase (AAAD, or DOPA decarboxylase, DDC).


Peripheral DDCIs incapable of crossing the protective blood-brain-barrier (BBB) are used in augmentation of L-DOPA (Levodopa) in the treatment of Parkinson's disease (PD) to block the peripheral conversion of L-DOPA into dopamine for the purpose of reducing adverse side effects.[1] Combined l-dopa and DDCI therapy does not inherently decrease peripheral cardiovascular side effects of l-dopa administration; however, combined therapy potentiates the central effects of l-dopa by decreasing the dose-dependency 4-5 fold, therein allowing for effective Parkinson's Disease treatment without cardiovascular risk associated with high peripheral dopamine.[2][3]

List of DDCIs[edit]

  • Benserazide (Madopar, Prolopa, Modopar, Madopark, Neodopasol, EC-Doparyl, etc.)
  • Carbidopa (Lodosyn, Sinemet, Parcopa, Atamet, Stalevo, etc.)
  • Methyldopa (Aldomet, Aldoril, Dopamet, Dopegyt, etc.)
  • DFMD
  • 3',4',5,7-Tetrahydroxy-8-methoxyisoflavone [58262-89-8]


  1. ^ "Editorial: Dopa decarboxylase inhibitors". British Medical Journal. 4 (5939): 250–1. November 1974. doi:10.1136/bmj.4.5939.250. PMC 1612227Freely accessible. PMID 4425849. 
  2. ^ Cotzias, G. C., Papavasiliou, P. S., and Gellene, R., New England Journalof Medicine, 1969, 280, 337.
  3. ^ Yahr, M. D., in Advances in Neurology, ed. M. D. Yahr, p. vi, vol. 2. New York, Raven Press, 1973.